Overview

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Status:
RECRUITING
Trial end date:
2026-07-13
Target enrollment:
Participant gender:
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Phase:
PHASE1
Details
Lead Sponsor:
Aibin LiangMDPh.D.
Treatments:
Immunotherapy, Adoptive